

CITATION REPORT

List of articles citing

Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada

DOI: 10.1002/(sici)1099-0496(199910)28:43.O.co;2-2
Pediatric Pulmonology, 1999, 28, 231-41.

Source: <https://exaly.com/paper-pdf/30636226/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
157	Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. 1999 , 116, 639-46		157
156	Patterns of medical practice in cystic fibrosis: part I. Evaluation and monitoring of health status of patients. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. <i>Pediatric Pulmonology</i> , 1999 , 28, 242-7	3.5	35
155	Elusiveness of ideal approach to <i>Pseudomonas aeruginosa</i> infection complicating cystic fibrosis. 2000 , 356, 613-4		6
154	The German cystic fibrosis quality assurance project: clinical features in children and adults. 2001 , 17, 1187-94		24
153	Management of Pulmonary Disease in Patients with Cystic Fibrosis. 2001 , 14, 207-227		2
152	Spirometry in 3- to 6-year-old children with cystic fibrosis. 2002 , 166, 67-71		68
151	Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. <i>Thorax</i> , 2002 , 57, 596-601	7.3	199
150	Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids. 2002 , 4, 381-9		10
149	Demographic transition of the Swedish cystic fibrosis community--results of modern care. 2002 , 96, 681-5		31
148	Risk factors for <i>Burkholderia cepacia</i> complex colonization and infection among patients with cystic fibrosis. <i>Journal of Pediatrics</i> , 2002 , 141, 512-7	3.6	19
147	The rationale for aerosolized antibiotics. 2002 , 22, 71S-79S		28
146	Pharmaceutical considerations in aerosol drug delivery. 2002 , 22, 80S-85S		20
145	Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. <i>Journal of Pediatrics</i> , 2003 , 142, 624-30	3.6	292
144	[Epidemiological survey of bacteria isolated from the respiratory tract of cystic fibrosis patients]. 2003 , 9, 337-52		4
143	Factors influencing outcomes in cystic fibrosis: a center-based analysis. 2003 , 123, 20-7		169
142	Risk of physician-diagnosed asthma in the first 6 years of life. 2004 , 126, 1147-53		64
141	Pharmacoeconomic review of recombinant human DNase in the management of cystic fibrosis. 2004 , 4, 49-59		2

140	Association of observed family relationship quality and problem-solving skills with treatment adherence in older children and adolescents with cystic fibrosis. 2004 , 29, 343-53		122
139	Recurrent events analysis in the presence of time-dependent covariates and dependent censoring. 2004 , 66, 239-257		44
138	Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis. 2004 , 144, 127-33		20
137	Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. 2004 , 60, 67-74		28
136	Pulmonary exacerbations in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2004 , 37, 400-6	3.5	141
135	Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. 2004 , 23, 504-10		76
134	Epidemiology of cystic fibrosis-related diabetes. <i>Journal of Pediatrics</i> , 2005 , 146, 681-7	3.6	224
133	Overview of published evidence on outcomes with early diagnosis from large US observational studies. <i>Journal of Pediatrics</i> , 2005 , 147, S11-4	3.6	29
132	Bronchial artery embolization in adults with cystic fibrosis: impact on the clinical course and survival. 2006 , 17, 953-8		40
131	Clinical scoring systems in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2006 , 41, 602-17	3.5	30
130	Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. <i>Pediatrics</i> , 2007 , 119, e531-7	7.4	48
129	Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. 2007 , 176, 1084-9		144
128	Spirometry in early childhood in cystic fibrosis patients. 2007 , 131, 356-61		39
127	Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. <i>Pediatric Pulmonology</i> , 2007 , 42, 513-8	3.5	111
126	Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. <i>Journal of Pediatrics</i> , 2007 , 151, 134-9, 139.e1	3.6	328
125	The Streptococcus milleri group--an unrecognized cause of disease in cystic fibrosis: a case series and literature review. <i>Pediatric Pulmonology</i> , 2008 , 43, 490-7	3.5	85
124	Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. <i>Pediatric Pulmonology</i> , 2008 , 43, 739-44	3.5	17
123	Dornase alfa and progression of lung disease in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2008 , 43, S24-S28	3.5	5

122	Shifting patterns of inhaled antibiotic use in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2008 , 43, 874-81	3.5	50
121	The impact of incident methicillin resistant <i>Staphylococcus aureus</i> detection on pulmonary function in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2008 , 43, 1117-1123	3.5	64
120	Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. <i>Journal of Pediatrics</i> , 2008 , 153, 746-51	3.6	65
119	Patient registry analyses: seize the data, but caveat lector. <i>Journal of Pediatrics</i> , 2008 , 153, 733-5	3.6	27
118	Bronchiectasis. 2008 , 999-1003		
117	Prevention of chronic <i>Pseudomonas aeruginosa</i> infection in people with cystic fibrosis. <i>Expert Review of Respiratory Medicine</i> , 2009 , 3, 349-61	3.8	6
116	The impact of MRSA on lung function in patients with cystic fibrosis. 2009 , 179, 734-5; author reply 735		22
115	Eradication of early <i>Pseudomonas</i> infection in cystic fibrosis. 2009 , 6, 99-107		26
114	Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. <i>Pediatrics</i> , 2009 , 123, 407-12	7.4	116
113	Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. <i>Journal of Pediatrics</i> , 2009 , 155, 634-9.e1-4	3.6	73
112	IL1B polymorphisms modulate cystic fibrosis lung disease. <i>Pediatric Pulmonology</i> , 2009 , 44, 580-93	3.5	43
111	Time course and recovery of arterial blood gases during exacerbations in adults with Cystic Fibrosis. <i>Journal of Cystic Fibrosis</i> , 2009 , 8, 9-13	4.1	4
110	The role of inhaled corticosteroids in the management of cystic fibrosis. 2009 , 11, 101-13		31
109	Characterizing aggressiveness and predicting future progression of CF lung disease. <i>Journal of Cystic Fibrosis</i> , 2009 , 8 Suppl 1, S15-9	4.1	41
108	Inhaled corticosteroids for cystic fibrosis. 2009 , CD001915		17
107	Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. 2010 , 137, 642-50		81
106	Vitamin K supplementation for cystic fibrosis. 2010 ,		3
105	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2010 , 45, 1156-66	3.5	34

104	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. <i>Pediatric Pulmonology</i> , 2010 , 45, 1167-72	4.1	47
103	Year-to-year changes in lung function in individuals with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2010 , 9, 250-6	4.1	81
102	Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. <i>Journal of Cystic Fibrosis</i> , 2010 , 9, 332-8	4.1	35
101	Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. 2011 , 183, 1463-71		207
100	Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. <i>Journal of Cystic Fibrosis</i> , 2011 , 10, 453-9	4.1	27
99	Vitamin K supplementation for cystic fibrosis. 2011 , CD008482		8
98	Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. <i>Journal of Pediatrics</i> , 2011 , 159, 819-824.e1	3.6	27
97	Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2011 , 46, 36-44	3.5	69
96	Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2011 , 46, 545-53	3.5	66
95	Infections and Diseases of the Lungs, Pleura, and Mediastinum. 2012 , 855-880		2
94	Benchmarking to improve the quality of cystic fibrosis care. 2012 , 18, 596-601		23
93	Immune responses in cystic fibrosis: are they intrinsically defective?. 2012 , 46, 715-22		62
92	Interventions for the eradication of methicillin resistant <i>Staphylococcus aureus</i> in people with cystic fibrosis. 2012 ,		
91	Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2012 , 11, 78-83	4.1	52
90	Multiple antibiotic-resistant <i>Pseudomonas aeruginosa</i> and lung function decline in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2012 , 11, 293-9	4.1	42
89	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2012 , 11, 405-11	4.1	83
88	Inhaled corticosteroids for cystic fibrosis. 2012 , 11, CD001915		15
87	Lung function decline from adolescence to young adulthood in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2012 , 47, 135-43	3.5	77

86	Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2012 , 47, 966-72	3.5	12
85	Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. <i>Journal of Cystic Fibrosis</i> , 2013 , 12, 461-7	4.1	95
84	Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005. <i>Journal of Cystic Fibrosis</i> , 2013 , 12, 332-7	4.1	16
83	Testing the feasibility of a National Spina Bifida Patient Registry. 2013 , 97, 36-41		38
82	A semiparametric approach to estimate rapid lung function decline in cystic fibrosis. 2013 , 23, 771-7		36
81	How the airway smooth muscle in cystic fibrosis reacts in proinflammatory conditions: implications for airway hyper-responsiveness and asthma in cystic fibrosis. 2013 , 1, 137-47		33
80	Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. <i>Journal of Pediatrics</i> , 2013 , 163, 1152-7.e2	3.6	25
79	Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. 2013 , CD009650		8
78	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2013 , 48, 666-73	3.5	82
77	Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms. <i>Pediatric Pulmonology</i> , 2013 , 48, 649-57	3.5	33
76	Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis. <i>Annals of the American Thoracic Society</i> , 2013 , 10, 213-9	4.7	36
75	Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2013 , 48, 943-53	3.5	25
74	Vitamin K supplementation for cystic fibrosis. 2013 , CD008482		10
73	Inhaled dry powder mannitol in cystic fibrosis. 2014 , 2, 751-757		2
72	Early childhood wheezing is associated with lower lung function in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2014 , 49, 745-50	3.5	18
71	Liver involvement in the Hispanic population of North America with cystic fibrosis. 2014 , 59, 476-9		7
70	Asthma and cystic fibrosis: a tangled web. <i>Pediatric Pulmonology</i> , 2014 , 49, 205-13	3.5	26
69	Clinical use of tobramycin inhalation solution (TOBI [®]) shows sustained improvement in FEV1 in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2014 , 49, 529-36	3.5	16

68	Severe pulmonary exacerbation in cystic fibrosis caused by cat allergy. 2014 , 15 Suppl 1, 29-31		
67	European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2014 , 13 Suppl 1, S43-59	4.1	37
66	Inhaled corticosteroids for cystic fibrosis. 2014 , CD001915		14
65	Managing <i>Pseudomonas aeruginosa</i> respiratory infections in cystic fibrosis. 2015 , 28, 547-56		50
64	Vitamin K supplementation for cystic fibrosis. 2015 , 1, CD008482		13
63	Interventions for the eradication of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in people with cystic fibrosis. <i>The Cochrane Library</i> , 2015 , CD009650	5.2	14
62	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2015 , 50, 856-62	3.5	13
61	NETs and CF Lung Disease: Current Status and Future Prospects. 2015 , 4, 62-75		32
60	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. <i>Pediatric Pulmonology</i> , 2015 , 50, 431-40	3.5	33
59	Pulmonary function outcomes for assessing cystic fibrosis care. <i>Journal of Cystic Fibrosis</i> , 2015 , 14, 376-83.	3.1	11
58	C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations. 2016 , 6, 1000375		11
57	Clinical approach to the diagnosis and treatment of cystic fibrosis and CFTR-related disorders. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 1177-1186	3.8	8
56	Inhaled corticosteroids for cystic fibrosis. <i>The Cochrane Library</i> , 2016 , CD001915	5.2	18
55	Are CF carriers predisposed to asthma?. <i>Journal of Cystic Fibrosis</i> , 2016 , 15, 555-6	4.1	
54	Standardy opieki Europejskiego Towarzystwa Mukowiscydozy: zarządzanie jakością w zakresie mukowiscydozy. <i>Pediatrica Polska</i> , 2016 , 91, S59-S78	0.1	
53	Semiparametric Regression Estimation for Recurrent Event Data with Errors in Covariates under Informative Censoring. <i>International Journal of Biostatistics</i> , 2016 , 12,	1.3	4
52	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. <i>Journal of Pediatrics</i> , 2016 , 169, 116-21.e2	3.6	33
51	Use of FEV in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher. <i>Journal of Cystic Fibrosis</i> , 2017 , 16, 318-326	4.1	54

50	Risk factors for mortality before age 18 years in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2017 , 52, 909-915	3.5	44
49	Common clinical features of CF (respiratory disease and exocrine pancreatic insufficiency). <i>Presse Medicale</i> , 2017 , 46, e109-e124	2.2	6
48	Relationship of Antibiotic Treatment to Recovery after Acute FEV Decline in Children with Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 937-942	4.7	25
47	Data that empower: The success and promise of CF patient registries. <i>Pediatric Pulmonology</i> , 2017 , 52, S44-S51	3.5	15
46	Vitamin K supplementation for cystic fibrosis. <i>The Cochrane Library</i> , 2017 , 8, CD008482	5.2	3
45	FORWARD: A Registry and Longitudinal Clinical Database to Study Fragile X Syndrome. <i>Pediatrics</i> , 2017 , 139, S183-S193	7.4	28
44	Comparison of FEV reference equations for evaluating a cystic fibrosis therapeutic intervention. <i>Pediatric Pulmonology</i> , 2017 , 52, 1013-1019	3.5	6
43	Bronchodilators in cystic fibrosis: a critical analysis. <i>Expert Review of Respiratory Medicine</i> , 2017 , 11, 13-20	3.8	4
42	Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic Fibrosis. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	5
41	Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018 , 17, 496-502	4.1	9
40	Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 485-493	4.7	38
39	Epidemiology of CF: How registries can be used to advance our understanding of the CF population. <i>Journal of Cystic Fibrosis</i> , 2018 , 17, 297-305	4.1	49
38	Cystic fibrosis patient registries: A valuable source for clinical research. <i>Journal of Cystic Fibrosis</i> , 2018 , 17, 433-440	4.1	13
37	Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. <i>Pediatric Pulmonology</i> , 2018 , 53, 43-49	3.5	5
36	Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis. <i>Thorax</i> , 2018 , 73, 134-144	7.3	94
35	Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 225-233	4.7	21
34	Cystic Fibrosis Mortality in Childhood. Data from European Cystic Fibrosis Society Patient Registry. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	16
33	Cystic fibrosis year in review 2017. <i>Pediatric Pulmonology</i> , 2018 , 53, 1307-1317	3.5	1

32	Interventions for the eradication of meticillin-resistant <i>Staphylococcus aureus</i> (MRSA) in people with cystic fibrosis. <i>The Cochrane Library</i> , 2018 , 7, CD009650	5.2	9
31	Back to the source - Modern insights into pulmonary exacerbations and lung function decline from CF registry data. <i>Journal of Cystic Fibrosis</i> , 2018 , 17, 425-427	4.1	
30	Recombinant Human Deoxyribonuclease I. 2019 , 471-488		3
29	Cystic fibrosis - an example of personalized and precision medicine. <i>Apmis</i> , 2019 , 127, 352-360	3.4	15
28	Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure. <i>Journal of Cystic Fibrosis</i> , 2020 , 19, 114-118	4.1	2
27	Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020 , 19, 119-124	4.1	10
26	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2020 , 55, 828-834	3.5	8
25	Evaluating Clinical Effectiveness with CF Registries. 2020 ,		
24	Tolerance of 7% Hypertonic Saline in Pediatric Cystic Fibrosis Patients. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2020 , 33, 63-68	0.8	78
23	Vitamin K supplementation for cystic fibrosis. <i>The Cochrane Library</i> , 2020 , 6, CD008482	5.2	0
22	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. <i>Pediatric Pulmonology</i> , 2021 , 56, 823-836	3.5	3
21	Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome. <i>Current Allergy and Asthma Reports</i> , 2021 , 21, 9	5.6	1
20	Seasonal variation of lung function in cystic fibrosis: longitudinal modeling to compare a Midwest US cohort to international populations.. <i>Science of the Total Environment</i> , 2021 , 776,	10.2	1
19	Granulocytic Myeloid-Derived Suppressor Cells in Cystic Fibrosis. <i>Frontiers in Immunology</i> , 2021 , 12, 745384	3.4	0
18	Retracing changes in cystic fibrosis understanding and management over the past twenty years. <i>Journal of Cystic Fibrosis</i> , 2021 ,	4.1	0
17	Recombinant Human Deoxyribonuclease I. 2013 , 321-336		4
16	Pulmonary Exacerbations. <i>Respiratory Medicine</i> , 2020 , 181-198	0.2	1
15	Quality Improvement in Inflammatory Bowel Disease. 2017 , 685-695		1

14	Microbiologic investigation on patients with cystic fibrosis subjected to bilateral lung transplantation. <i>Transplantation</i> , 2001 , 72, 1575-7	1.8	3
13	Avaliaço evolutiva da espirometria na fibrose cstica. <i>Jornal De Pneumologia</i> , 2001 , 27, 130-136		10
12	Pulmonary function parameters and use of bronchodilators in patients with cystic fibrosis. <i>Jornal Brasileiro De Pneumologia</i> , 2013 , 39, 48-55	1.1	4
11	Mikrobiologie. 2001 , 75-119		
10	Epidemiologie der CF-Erkrankung. 2001 , 255-261		1
9	Infections and Diseases of the Lungs, Pleura, and Mediastinum. 2006 , 1001-1037		3
8	CYSTIC FIBROSIS. 2009 , 342-364		
7	Quality Improvement in Inflammatory Bowel Disease. 2013 , 547-554		
6	Ocular Manifestations of Pediatric Pulmonary Diseases. 2017 , 601-615		
5	Quality Improvement in Inflammatory Bowel Disease. 2008 , 631-639		
4	Laboratory biomarkers in the diagnosis and follow-up of treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. 1-24		
3	Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV1 decline. e20210237		0
2	Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. 2022 , 2022,		0
1	Quality Improvement in Inflammatory Bowel Disease. 2023 , 789-801		0